Neurocrine reports Q3 non-GAAP EPS $1.81, consensus $1.50
The Fly

Neurocrine reports Q3 non-GAAP EPS $1.81, consensus $1.50

Reports Q3 revenue $622.1M, consensus $600.63M. “With continued INGREZZA growth across the tardive dyskinesia and Huntington’s disease chorea indications, FDA Priority Review for crinecerfont in congenital adrenal hyperplasia, a deep neuroscience focused pipeline and a strong balance sheet, we are confident in our ability to help more patients than ever before,” said Kyle W. Gano, CEO.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App